» Articles » PMID: 23295277

Rate of Early/missed Colorectal Cancers After Colonoscopy in Older Patients with or Without Inflammatory Bowel Disease in the United States

Overview
Specialty Gastroenterology
Date 2013 Jan 9
PMID 23295277
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Patients with inflammatory bowel disease (IBD) have an increased risk for colorectal cancer (CRC). Previous studies on early/missed CRCs after colonoscopy excluded IBD patients. The aim of this study was to compare the rate of early/missed CRCs after colonoscopy among IBD and non-IBD patients, and identify factors associated with early/missed CRCs.

Methods: All patients in the Surveillance, Epidemiology and End-Results Medicare-linked database who were 67 years or older at colonoscopy during 1998-2005 and those who were subsequently diagnosed with CRC within 36 months were identified. CRCs diagnosed within 6 months of colonoscopy were categorized as detected CRCs; CRCs diagnosed 6-36 months after colonoscopy were categorized as early/missed CRCs. The rate of early/missed CRCs was calculated as number of early/missed CRCs divided by number of detected and early/missed CRCs. The χ(2) test and multivariate logistic regression were used in statistical analysis.

Results: Of 55,008 CRC patients (304 Crohn's disease; 544 ulcerative colitis (UC)), the rate of early/missed CRCs was 5.8% for non-IBD patients, 15.1% for Crohn's, and 15.8% for UC (P<0.001). Compared with older non-IBD patients, early/missed CRCs among older IBD patients were less likely right-sided (both P<0.05). In multivariate logistic regression, the risk of early/missed CRCs was three times as high for IBD patients (Crohn's odds ratio (OR), 3.07; 95% confidence interval (CI) 2.23-4.21; UC OR, 3.05; 95% CI, 2.44-3.81). Sensitivity analyses confirmed the robustness of this finding.

Conclusions: Older IBD patients had a higher rate of early/missed CRCs after colonoscopy. Our finding supports intensive surveillance colonoscopy for older IBD patients as recommended by guidelines.

Citing Articles

Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review.

Marabotto E, Kayali S, Buccilli S, Levo F, Bodini G, Giannini E Cancers (Basel). 2022; 14(17).

PMID: 36077786 PMC: 9454776. DOI: 10.3390/cancers14174254.


Characteristics of colorectal cancer and use of colonoscopy before colorectal cancer diagnosis among individuals with inflammatory bowel disease: A population-based study.

Hansen T, Nugent Z, Bernstein C, Samadder N, Murthy S, Singh H PLoS One. 2022; 17(8):e0272158.

PMID: 35913956 PMC: 9342763. DOI: 10.1371/journal.pone.0272158.


Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget.

Nunez F P, Quera R, Rubin D World J Gastrointest Endosc. 2022; 14(2):85-95.

PMID: 35316980 PMC: 8908328. DOI: 10.4253/wjge.v14.i2.85.


Risk of a post-colonoscopy colorectal cancer in patients with type 2 diabetes: a Danish population-based cohort study.

Troelsen F, Sorensen H, Pedersen L, Erichsen R BMJ Open Gastroenterol. 2021; 8(1).

PMID: 34952850 PMC: 8710863. DOI: 10.1136/bmjgast-2021-000786.


Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis.

Reznicek E, Arfeen M, Shen B, Ghouri Y Diseases. 2021; 9(4).

PMID: 34842672 PMC: 8628786. DOI: 10.3390/diseases9040086.